BMEA
Companies
NASDAQ
Biomea Fusion Inc.
Health Care
$1.91
-$1.97 (-50.77%)
Price Chart
Overview
About BMEA
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Market Cap
$148.8M
Volume
1.3M
Avg. Volume
1.3M
P/E Ratio
-0.6039157
Dividend Yield
0.00%
Employees
93.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.66
Low Correlation
Volatility
High (0.97)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BMEA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$148.8M
Volume1.3M
P/E Ratio-0.60
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 3, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025